Abstract

AtriCure, Inc. will report quarterly results on May 5, 2026, Post Market; this preview summarizes consensus revenue and earnings expectations, recent performance, and key factors likely to influence the print and subsequent share reaction.

Market Forecast

Consensus for the current quarter points to revenue of 139.81 million US dollars, implying year-over-year growth of 13.75%; adjusted EPS is projected at approximately -0.06, an improvement of about 74.28% versus the same period last year, while EBIT is forecast near -2.41 million US dollars, improving roughly 75.10% year over year. Gross margin guidance for the quarter is not provided in the collected forecasts, but the prior quarter’s gross margin stood at 74.97%, offering a recent benchmark for investors assessing profitability; net margin guidance is similarly unavailable in forecasts.

The main commercial drivers remain procedure-focused product lines that have supported double-digit revenue growth, with management’s execution on US account expansion and continued international traction expected to underpin volume resilience. Among the portfolio, AtriClip (left atrial appendage occlusion) is widely viewed as the highest-potential contributor in the near term, with trailing revenue of 178.13 million US dollars; year-over-year growth at the segment level was not disclosed in the available materials.

Last Quarter Review

In the most recently reported quarter, AtriCure delivered revenue of 140.50 million US dollars, up 13.05% year over year, with a gross profit margin of 74.97%, GAAP net profit attributable to shareholders of 1.76 million US dollars for a net margin of 1.25%, and adjusted EPS of 0.04, up 150.00% year over year. Both revenue and earnings exceeded consensus expectations, with revenue modestly above the aggregate estimate and adjusted EPS outperforming relative to a negative consensus baseline.

On the business front, performance reflected healthy procedure volumes and favorable product mix, supporting high-70s gross margin resilience even as operating expenses remained aligned with commercialization priorities and clinical programs. By segment, recent revenue contributions were led by AtriClip devices at 178.13 million US dollars, open-heart ablation at 143.85 million US dollars, international sales at 99.16 million US dollars, pain management at 81.92 million US dollars, and minimally invasive ablation at 31.48 million US dollars; year-over-year changes by segment were not disclosed in the collected dataset.

Current Quarter Outlook (with major analytical insights)

Main Business: Core Procedure-Driven Revenues

Consensus revenue of 139.81 million US dollars implies mid‑teens year-over-year growth, alongside an expected sequential step-down from the fourth quarter’s seasonal peak to a first-quarter run rate. The forecast assumes continued traction across the core procedure ecosystem, with utilization in established cardiac surgery sites and incremental account additions sustaining unit demand for the company’s therapeutic portfolio. Given the prior quarter’s gross margin of 74.97%, investors will look for signals that product mix and manufacturing scale are holding steady, especially as volumes normalize from Q4 highs.

Operating leverage will likely be in focus. While consensus anticipates an adjusted EPS loss of about -0.06 this quarter, the implied year-over-year improvement suggests expenses are being managed against a growing base of recurring procedure demand. The pathway to sustained profitability remains rooted in consistent volume growth, stable pricing, and disciplined spending as commercialization activities continue. Any commentary on sales force productivity, account ramp times, and reorder cadence could help investors assess whether mid‑teens growth is converting into margin improvement evenly across the year rather than being back-half loaded.

Sequential dynamics matter for modeling. Historically, many procedure-centric businesses see Q1 contraction versus Q4 due to scheduling patterns; the current estimate aligns with that pattern yet still calls for robust year-over-year expansion. Investors should compare booked-case trends and reorder metrics alongside distributor inventory behavior to identify whether the current trajectory supports reacceleration into Q2 and beyond. A reiteration of full-year growth goals would likely be viewed as constructive, especially if management frames expected drivers for the back half of 2026.

Most Promising Segment: AtriClip Left Atrial Appendage Management

AtriClip remains a focal point for durable revenue expansion and margin support. The segment’s trailing revenue base of 178.13 million US dollars underscores its scale within the portfolio, and its profile as a procedure-enabling product makes it sensitive to surgical volumes, training reach, and account penetration efficiency. In the current quarter, investors will look for continuity in utilization and new account conversions, which can offset routine Q1 procedure-seasonality effects relative to Q4 peaks.

From a profitability standpoint, AtriClip’s contribution is critical because higher-value implants typically support more resilient gross margins versus lower-value consumables. As consensus does not provide a specific gross margin forecast, the prior quarter’s 74.97% serves as a recent datapoint, and AtriClip’s mix could help keep margins stable even if operating expenses expand with new customer acquisition. Commentary on reorder rates, surgeon training throughput, and average selling prices would help refine how AtriClip’s growth translates into corporate-level operating leverage through the year.

Strategically, a consistent cadence of clinical education and procedural standardization can help reduce variability in case times and outcomes, supporting adoption. While the available materials do not provide segment-specific year-over-year growth for AtriClip, the overall company forecast of 13.75% year-over-year revenue growth suggests a supportive backdrop. Any update pointing to additional account wins, deepening penetration within existing accounts, or incremental geographies contributing to demand would likely reinforce sell‑side views that AtriClip remains a primary pillar of near-term growth.

Key Stock-Price Drivers This Quarter

- Profitability trajectory. The market will be monitoring whether the combination of mid‑teens year-over-year revenue growth and disciplined spending can compress losses in slower seasonal quarters. With consensus calling for an adjusted EPS of roughly -0.06 and EBIT near -2.41 million US dollars, investors will parse commentary on gross margin mix and the timing of operating cost growth to judge whether profitability targets for the year are achievable without outsized back-half dependence.

- Gross margin stability. The recent 74.97% gross margin sets a high bar. Sustaining this level hinges on product mix (including higher-value implants and advanced ablation tools), manufacturing efficiency, and logistics costs. Any confirmation that margins are tracking in the mid‑70s despite sequential revenue normalization would be viewed as supportive for valuation frameworks that emphasize operating leverage through 2026.

- Commercial execution and account expansion. Updates on sales-force productivity, conversion timelines, and reorder cadence will matter for modeling 2026 growth. Given the revenue estimate’s year-over-year expansion, the street will look for qualitative color on pipeline health and account momentum that can backstop continued mid‑teens growth through midyear.

- Clinical and regulatory developments. The company’s ongoing clinical study activity and related updates can influence adoption, reimbursement visibility, and physician behavior. While the collected materials flag activity in clinical programs, investors will focus on concrete milestones that can translate into nearer-term utilization, especially if supported by training initiatives and procedural workflow refinements.

- Sell‑side recalibration and sentiment. The quarter arrives amid a mix of Buy ratings and a couple of downgrades earlier in the year. Post‑print, guidance color and margin commentary could prompt rapid sentiment shifts, particularly if revenue growth remains in the mid‑teens while profitability improves in line with consensus. Clarity on full‑year cadence could reduce uncertainty around the pace of operating leverage.

Analyst Opinions

The balance of recent views skews positive. Counting items in the January 1, 2026 to April 28, 2026 window, we observe a majority of bullish stances versus downgrades: multiple Buys from BTIG, Piper Sandler, and UBS outweigh Neutral or Market Perform moves from JPMorgan and Oppenheimer. On a count basis, bullish opinions outnumber cautious/neutral takes by roughly five to two, indicating a clear positive lean into the print.

- BTIG (Marie Thibault) reiterated a Buy rating with a 54.00 US dollars target, emphasizing sustained outperformance, manageable competitive pressures, and undervalued growth. This perspective aligns with the mid‑teens revenue growth now embedded in consensus, and it implies confidence that the company can translate volume momentum into steady gross margin and gradual operating leverage. BTIG’s stance effectively sets a framework in which procedural growth and portfolio resilience offset seasonal fluctuations and continue to support double-digit annual expansion.

- Piper Sandler maintained its Buy rating, reinforcing the view that execution around procedural adoption remains intact. While no explicit quarterly numbers were cited in the collected materials, the tone corresponds with expectations for high‑single to low‑double-digit sequential normalization from Q4 and mid‑teens year-over-year expansion in Q1, with gross margin durability remaining a watchpoint rather than a structural concern. Piper’s posture suggests that, provided revenue lands near the 139.81 million US dollars consensus and margins do not materially underperform Q4’s 74.97%, the medium‑term thesis remains unchanged.

- UBS maintained a Buy rating and adjusted its price target to 55.00 US dollars, signaling that model updates incorporate ongoing revenue growth and improving earnings power. UBS’s view dovetails with the forecasted year-over-year improvements in EBIT and adjusted EPS despite a modest seasonal loss in the quarter. Their framework implies that, if management reinforces full-year growth cadence and cost discipline, the shares can continue to re-rate on better visibility into profitability progression.

In contrast, JPMorgan downgraded the shares to Neutral with a target cut to 36.00 US dollars, and Oppenheimer reduced its rating to Market Perform. These moves add a note of caution around valuation and near-term execution risks. However, they represent a minority of recent opinions and were issued prior to the latest set of consensus revisions that now embed a 13.75% year-over-year revenue growth outlook for the quarter and material year-over-year improvement in operating metrics. The preponderance of updated Buy ratings indicates that most analysts expect the revenue trajectory to remain constructive and the operating loss to narrow year over year.

Synthesizing these views, the majority opinion can be summarized as constructive into the print: revenue growth in the mid‑teens year over year, a sequential moderation consistent with seasonality, and margins that remain anchored near the recent mid‑70s reference point, collectively supporting a pathway to improved earnings power through 2026. Analysts emphasizing the Buy case also flag AtriClip’s contribution and continued expansion of procedural adoption as primary underpinnings of the model. Achieving or modestly beating the 139.81 million US dollars revenue consensus, while keeping gross margin behaviorally consistent with the prior quarter and demonstrating continued operating expense discipline, would likely validate the bullish stance reflected in the current ratio of favorable to cautious research opinions.